Edition:
United States

Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

11.47USD
27 Jun 2017
Change (% chg)

$-0.55 (-4.58%)
Prev Close
$12.02
Open
$12.02
Day's High
$12.10
Day's Low
$11.46
Volume
3,622,620
Avg. Vol
4,150,749
52-wk High
$23.44
52-wk Low
$9.45

Latest Key Developments (Source: Significant Developments)

Horizon Pharma Plc says district court upheld validity of two patents covering Vimovo
7:00am EDT 

June 27 (Reuters) - Horizon Pharma Plc :Horizon Pharma Plc announces district court decision to uphold Vimovo (naproxen/esomeprazole magnesium) patents.Horizon Pharma Plc - United States district court upheld validity of two Horizon Pharma patents covering Vimovo.  Full Article

Horizon Pharma sees 2017 net sales between $985 mln - $1.02 bln
Friday, 23 Jun 2017 11:00am EDT 

June 23 (Reuters) - Horizon Pharma Plc ::Full-year 2017 net sales are now expected to be in a range of $985 million to $1.020 billion.Full-year 2017 adjusted ebitda guidance range of $315 million to $350 million has not changed.  Full Article

Horizon Pharma to sell Procysbi, Quinsair EU marketing rights
Tuesday, 23 May 2017 04:05pm EDT 

May 23 (Reuters) - Horizon Pharma Plc :Horizon pharma plc announces agreement to sell european marketing rights to procysbi® (cysteamine bitartrate) delayed-release capsules and quinsair™ (levofloxacin inhalation solution) in europe, middle east and africa (emea) regions to chiesi farmaceutici.Horizon pharma plc - deal for an upfront payment of $70 million.Horizon pharma plc - horizon will maintain control of manufacturing supply in emea regions through its third party supplier..Horizon pharma plc - in addition, horizon will maintain marketing rights for procysbi and quinsair in united states, canada and latin america.Horizon pharma - co anticipates a reduction of approximately $15 million in full-year 2017 net sales related to procysbi and quinsair in emea regions.Horizon pharma plc - divested subsidiary has facilities in netherlands, france and germany and has approximately 40 employees.Horizon pharma plc - anticipates a reduction of approximately $15 million in full-year 2017 net sales related to procysbi and quinsair in emea regions.Horizon pharma plc - no change to horizon's full-year 2017 adjusted ebitda guidance range of $315 million to $350 million.Sees fy 2017 revenue $985 million to $1.02 billion.Horizon pharma plc - assuming a second-quarter 2017 transaction close, horizon anticipates a neutral impact on its full-year 2017 adjusted ebitda.Fy2017 revenue view $999.4 million -- Thomson Reuters I/B/E/S.  Full Article

Nuvo Pharmaceuticals announces district court decision to uphold U.S. Pennsaid 2% patent
Monday, 15 May 2017 07:30am EDT 

May 15 (Reuters) - Nuvo Pharmaceuticals Inc :Nuvo Pharmaceuticals announces district court decision to uphold U.S. Pennsaid 2% patent.Court upheld validity of Horizon Pharma's U.S. patent covering Pennsaid 2%.Pennsaid 2% has multiple orange book listed patents with terms that extend to 2030.  Full Article

Horizon Pharma announces U.S. district court's decision to uphold PENNSAID 2% w/w patent
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Horizon Pharma Plc :Horizon pharma plc says district court decision to uphold pennsaid (diclofenac sodium topical solution) 2% w/w patent.  Full Article

Horizon Pharma reports Q1 loss per share of $0.56
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Horizon Pharma Plc :Announces first-quarter 2017 results and revises full-year 2017 net sales and adjusted ebitda guidance.Q1 sales $220.9 million versus I/B/E/S view $247.9 million.Sees FY 2017 sales $1.0 billion to $1.035 billion.Qtrly loss per share $0.56.Qtrly non-gaap earnings per share $0.21.Revised its full-year 2017 net sales guidance range to $1.000 billion to $1.035 billion from $1.240 billion to $1.290 billion.Revised its full-year 2017 adjusted EBITDA guidance to $315 million to $350 million from $525 million to $575 million.Raising its estimate of peak annual net sales for Krystexxa to $400 million from $250 million for FY.Announces board of directors' authorization of share repurchase program for approximately 10 percent of shares outstanding.FY2017 revenue view $1.26 billion -- Thomson Reuters I/B/E/S.Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma Plc to acquire River Vision Development Corp
Monday, 8 May 2017 06:55am EDT 

May 8 (Reuters) - Horizon Pharma Plc : :Horizon Pharma Plc announces agreement to acquire River Vision Development Corp and teprotumumab (rv001), a biologic in late-stage development for rare eye disease.Horizon Pharma Plc - pivotal trial of teprotumumab in thyroid eye disease (ted) expected to begin in second half of 2017.Horizon Pharma Plc - deal for upfront cash payment of $145 million.Horizon Pharma - Horizon anticipates a potential peak annual sales opportunity for Teprotumumab, if approved, in excess of $250 million in United States.  Full Article

Horizon Pharma says FDA approved to expand age range for Ravicti
Monday, 1 May 2017 07:00am EDT 

May 1 (Reuters) - Horizon Pharma Plc -:Horizon Pharma Plc announces FDA approval to expand the age range for Ravicti® (glycerol phenylbutyrate) oral liquid to people with urea cycle disorders two months of age and older.  Full Article

Horizon Pharma Q4 adjusted earnings per share $0.64
Monday, 27 Feb 2017 07:00am EST 

Horizon Pharma Plc : Horizon pharma plc announces fourth-quarter and full-year 2016 financial results and provides full-year 2017 net sales and adjusted ebitda guidance . Q4 non-gaap earnings per share $0.64 . Q4 sales $310.3 million versus i/b/e/s view $309.6 million . Q4 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Sees fy 2017 sales $1.24 billion to $1.29 billion . Q4 gaap loss per share $0.81 . Sees fy 2017 sales up 19 to 23 percent .Horizon pharma plc sees full-year 2017 adjusted ebitda guidance of $525 million to $575 million.  Full Article

Horizon Pharma estimates that its cash and cash equivalents were approximately $500 mln
Tuesday, 10 Jan 2017 09:02am EST 

Horizon Pharma Plc : Estimates that its cash and cash equivalents as of December 31 were approximately $500 million . Estimates total principal amount of its indebtedness was approximately $1,945 million as of December 31 .Sees for 2016 fiscal year, net sales from its primary care medicines were approximately $600 million in aggregate.  Full Article

More From Around the Web